Agilent Technologies, Inc. (NYSE:A) Shares Sold by Hancock Whitney Corp

by · The Cerbat Gem

Hancock Whitney Corp trimmed its holdings in Agilent Technologies, Inc. (NYSE:A – Free Report) by 48.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,513 shares of the medical research company’s stock after selling 9,709 shares during the quarter. Hancock Whitney Corp’s holdings in Agilent Technologies were worth $1,412,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Dauntless Investment Group LLC purchased a new position in shares of Agilent Technologies during the 4th quarter valued at approximately $267,000. Integrated Wealth Concepts LLC boosted its stake in shares of Agilent Technologies by 24.5% during the 4th quarter. Integrated Wealth Concepts LLC now owns 3,413 shares of the medical research company’s stock worth $458,000 after acquiring an additional 671 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Agilent Technologies by 9.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 218,494 shares of the medical research company’s stock worth $29,352,000 after acquiring an additional 18,500 shares in the last quarter. CSM Advisors LLC increased its stake in shares of Agilent Technologies by 2.7% in the 4th quarter. CSM Advisors LLC now owns 21,052 shares of the medical research company’s stock valued at $2,828,000 after purchasing an additional 550 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its holdings in Agilent Technologies by 76.6% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 10,902 shares of the medical research company’s stock worth $1,465,000 after purchasing an additional 4,727 shares during the period.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on A. Barclays decreased their target price on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Jefferies Financial Group decreased their price objective on shares of Agilent Technologies from $135.00 to $116.00 and set a “hold” rating on the stock in a report on Monday, April 21st. TD Cowen boosted their target price on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research note on Thursday, April 10th. Wells Fargo & Company decreased their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating on the stock in a research note on Thursday, April 17th. Finally, Robert W. Baird cut their price objective on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $143.00.

Check Out Our Latest Report on Agilent Technologies

Insiders Place Their Bets

In other news, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the transaction, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel K. Podolsky sold 1,819 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Stock Performance

NYSE A opened at $106.31 on Friday. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35. The firm has a market capitalization of $30.31 billion, a P/E ratio of 24.44, a price-to-earnings-growth ratio of 3.02 and a beta of 1.19. The stock’s fifty day moving average is $116.40 and its two-hundred day moving average is $131.09. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20.

Agilent Technologies (NYSE:A – Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. On average, research analysts anticipate that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st were given a $0.248 dividend. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.93%. Agilent Technologies’s payout ratio is 22.76%.

About Agilent Technologies

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

See Also

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).